written on 21.03.2014
Tags:
,

J&J's Velcade cleared by U.K. for first-line myeloma treatment in about-face

TAGS: ,

The U.K.'s National Institute for Health and Care Excellence has come around on Johnson & Johnson's Velcade as a first-line treatment for the blood cancer multiple myeloma. It approved the drug for the new use today, four months after initially saying it was unconvinced the benefits of the drug outweighed its costs.

Latest Report